United Therapeutics generates 41% net margins and ranks best-in-class on margins among specialty pharmaceutical peers, but severe product concentration where Tyvaso DPI and Nebulized Tyvaso together account for 59% of revenue, combined with 3 earnings misses in 4 quarters, makes the current risk profile unfavorable for new positions.
Thesis pillars
- Best In Class Pharma Margins→Stable
- Product Concentration Tyvaso↑Improving
- Earnings Miss Trajectory↑Improving
- +1 more pillar — see the Why tab for full reasoning
United Therapeutics Corporation (UTHR) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $490.16, but acceptable to hold if already in. Reasons: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty.
United Therapeutics markets five therapies for pulmonary arterial hypertension and rare diseases — Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Unituxin — generating approximately $3.16 billion in total revenues in 2025. Tyvaso DPI and Nebulized Tyvaso together... Read more
Hold if already holding. Not a fresh buy at $490.16, but acceptable to hold if already in. Reasons: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.2/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, no SEC red flags, earnings proximity 54d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: moderate.
Recent developments
updated 2026-09-04Recent Developments — United Therapeutics Corporation
Latest news
- NEWS Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist? - Moomoo — Moomoo neutral
- NEWS Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist? - moomoo.com — moomoo.com neutral
- NEWS UTHR Looks 35.2% Overvalued on GF Value™ - GuruFocus — GuruFocus negative
- NEWS UTHR|United Therapeutics Corp|Price:525.965|Chg%:+1.265 - TradingKey — TradingKey neutral
- NEWS United Therapeutics chairperson & CEO Martine Rothblatt sells $5.4m in stock - Investing.com — Investing.com negative
Generated 2026-09-04T15:07:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTyvaso DPI and Nebulized Tyvaso59%10-K Item 1: 'combined Tyvaso DPI and Nebulized Tyvaso net product sales, representing 59 percent...of our total revenues for the years ended December 31, 2025'
- HIGHCustomerAccredo and CVS Specialty10-K Item 1A: 'we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty'
- HIGHSupplierMannKind Corporation10-K Item 1A: 'We rely entirely on MannKind to manufacture Tyvaso DPI finished drug product and inhalers for us, with no plans to develop an alternate or backup supply arrangement'
- HIGHSupplierDEKA10-K Item 1A: 'We rely entirely on DEKA and its affiliates to manufacture the Remunity and RemunityPRO Pumps'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Revenue shrinking — -1.9% YoY. Growth thesis broken unless recovery story develops.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $490.16, but acceptable to hold if already in. Reasons: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $577.97 (+17.9%), stop $462.70 (−5.9%), A.R:R 3.2:1. Score 5.2/10, moderate confidence.
Take-profit target: $577.97 (+17.9% upside). Target $577.97 (+17.9%), stop $462.70 (−5.9%), A.R:R 3.2:1. Stop-loss: $462.70.
Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty; Weak growth.
United Therapeutics Corporation trades at a P/E of 17.6 (forward 16.3). TrendMatrix value score: 6.2/10. Verdict: Hold.
22 analysts cover UTHR with a consensus score of 4.1/5. Average price target: $664.
What does United Therapeutics Corporation do?United Therapeutics markets five therapies for pulmonary arterial hypertension and rare diseases — Tyvaso DPI,...
United Therapeutics markets five therapies for pulmonary arterial hypertension and rare diseases — Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Unituxin — generating approximately $3.16 billion in total revenues in 2025. Tyvaso DPI and Nebulized Tyvaso together accounted for 59% of revenues; substantially all treprostinil revenues flow through two distributors, Accredo and CVS Specialty, with no FDA-approved backup manufacturing site for Orenitram or Unituxin.